Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB12066 PK and Safety in Healthy Male Volunteers
NCT02338856Phase 1Completed
- Sponsor
- Yungjin Pharm. Co., Ltd.
- Start
- Jan 2015
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic syndrome comparing MB12066 200mg with Placebo (2 arms). Primary endpoint: Number of reported adverse events. Started Jan 2015; status: completed.
02
Drugs
ARQ761
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT02338856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338856.